Literature DB >> 9476110

Complement factors and their receptors.

J A Ember1, T E Hugli.   

Abstract

In summary, recent advances in molecular cloning of anaphylatoxins and the anaphylatoxin receptors add new dimensions to our investigations and understanding of the molecular mechanisms involved in anaphylatoxin action. Combining knowledge accumulated from peptide modeling of the ligands with mutagenesis studies of these ligands and their receptors makes it possible to more accurately model interactive sites and understand the sequence of molecular interactions required for cellular activation. In addition, these new developments provide valuable tools for investigating, yet unknown, activities and cellular targets of the anaphylatoxin molecules.

Mesh:

Substances:

Year:  1997        PMID: 9476110     DOI: 10.1016/s0162-3109(97)00088-x

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  23 in total

1.  Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor.

Authors:  J Sun; J A Ember; T H Chao; Y Fukuoka; R D Ye; T E Hugli
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

Review 2.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

Review 3.  A journey with Tony Hugli up the inflammatory cascade towards the auto-digestion hypothesis.

Authors:  Geert W Schmid-Schönbein
Journal:  Int Immunopharmacol       Date:  2007-08-09       Impact factor: 4.932

4.  The rickettsial OmpB β-peptide of Rickettsia conorii is sufficient to facilitate factor H-mediated serum resistance.

Authors:  Sean P Riley; Jennifer L Patterson; Juan J Martinez
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

5.  Efficient osteoclast differentiation requires local complement activation.

Authors:  Zhidan Tu; Hong Bu; James E Dennis; Feng Lin
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

6.  Pathogenic Rickettsia species acquire vitronectin from human serum to promote resistance to complement-mediated killing.

Authors:  Sean P Riley; Jennifer L Patterson; Samantha Nava; Juan J Martinez
Journal:  Cell Microbiol       Date:  2013-12-13       Impact factor: 3.715

7.  Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Authors:  Yoshihiro Fukuoka; Han-Zhang Xia; Laura B Sanchez-Muñoz; Anthony L Dellinger; Luis Escribano; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.

Authors:  Kwang-Seok Oh; Mee-Hyang Kweon; Ki-Hyeong Rhee; Keyong Ho Lee; Ha-Chin Sung
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

9.  The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen.

Authors:  Seiji Kawamoto; Ali Yalcindag; Dhafer Laouini; Scott Brodeur; Paul Bryce; Bao Lu; Alison A Humbles; Hans Oettgen; Craig Gerard; Raif S Geha
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Authors:  Lavinia M Proctor; Thiruma V Arumugam; Ian Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.